Physician profile
Swetha Kandula
NPI 1861604795
$2,720.77
in general payments reported to CMS, 2019-2025
26 companies · $973 in 2025
The $973 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2020: $100 · 2021: $55.99 · 2022: $602 · 2023: $368 · 2024: $472 · 2025: $973.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,718 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,717.99 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $569.88 | 2019-2022 | |
| Revance Therapeutics, INC. | $372.69 | 2024-2025 | Daxxify |
| Sun Pharmaceutical Industries INC. | $254.75 | 2023-2025 | Winlevi, Absorica Ld |
| Pfizer INC. | $210.14 | 2021-2025 | |
| Amgen INC. | $199.99 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $196.77 | 2022-2025 | Opzelura |
| Lilly USA, LLC | $162.71 | 2022-2024 | Olumiant, Taltz |
| Abbvie INC. | $119.14 | 2023-2025 | |
| Janssen Biotech, INC. | $94.99 | 2024 | Tremfya |
| Arcutis Biotherapeutics, INC. | $71.18 | 2023-2024 | Zoryve |
| Galderma Laboratories, L.P. | $64.37 | 2022-2025 | Nemluvio |
| Mayne Pharma Commercial LLC | $53.11 | 2023-2025 | |
| Organon LLC | $38.07 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $35.74 | 2025 | Libtayo |
| Botanix Sb INC | $34.41 | 2025 | Sofdra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $34.16 | 2025 | Klisyri |
| Solta Medical, A Division of Bausch Health US, LLC | $32.85 | 2025 | |
| Verrica Pharmaceuticals INC. | $26.79 | 2024 | Ycanth |
| Epi Health, LLC | $25.01 | 2022 | |
| Convatec INC. | $22.13 | 2025 | |
| Leo Pharma INC. | $21.75 | 2025 | Anzupgo |
| Lnhc, INC | $17.68 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.89 | 2023 | Spevigo |
| Dermavant Sciences, INC. | $16.17 | 2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $15.45 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swetha Kandula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.